TrialReader


Investigation on the Sustained Effect of Anthocyanins on Endothelial Function in Postmenopausal Women

NCT02517801 — Not applicable, Completed, 20 participants, Heinrich-Heine University, Duesseldorf

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT02517801, acronym Anthocyanins
StatusCompleted
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: double, prevention
Enrollment20 (Actual)
SponsorHeinrich-Heine University, Duesseldorf (Other)
ConditionsPost-menopausal Women
InterventionsAnthocyanin capsules, placebo capsules (Dietary supplement)
Datesstart 2015-01-01, primary completion 2015-09-01, completion 2015-09-01, first posted 2015-08-07, last updated 2015-11-03
Locations1 site in Germany

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Post-menopausal Women All trials of Anthocyanin capsules All trials of placebo capsules

-Summary

Anthocyanins are the most common polyphenols in berries and red wine, along with other flavonoids, phenolic acids, minerals and vitamins. Anthocyanins are extensively metabolized and they are transformed into glucuronides and phenolic acids. The investigators have recently shown that the acute consumption of blueberries leads to an increase in endothelium-dependent vasodilation measured as flow-mediated dilatation (FMD) in young male volunteers. There were significant correlations of these effects with the plasma concentration of phenolic acids and anthocyanin metabolites. Therefore, the present study aims at understanding to which extent the anthocyanins contained in berries are related with positive effects in endothelial function. A large part of the absorbed anthocyanin circulate in the blood in as methyl, glucuronyl and sulfate metabolites, as well as phenolic acids. The formation of these metabolites begins right as early as 2h after consumption due to metabolism at the small intestine and a second plasmatic peak occurs around 6h due the metabolism of colonic bacteria. Whether and which metabolites are associated with biological effects and the mechanisms underlying this effect remains unclear.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Anthocyanin capsulesExperimentalDietary Supplement: Anthocyanin capsulesChronic intake of 2 capsules for 30 days (2x daily)
placebo capsulesPlacebo comparatorDietary Supplement: placebo capsulesChronic intake of 2 capsules for 30 days (2x daily)
  • Anthocyanin capsules (Dietary supplement): Chronic intake of 2 capsules for 30 days (2x daily). Capsules with 80 mg of anthocyanins.
  • placebo capsules (Dietary supplement): Chronic intake of 2 capsules for 30 days (2x daily). 2 capsules devoid of anthocyanins.

+Outcome measures

Primary outcomes

  • Endothelial function [Baseline and on day 30]: Measured by Flow mediated dilation (FMD) at 0 and 2 hours postconsumption

Secondary outcomes

  • Pulse wave velocity [Baseline and on day 30]: measured by SphygmoCor at 0 and 2 hours postconsumption
  • Central blood pressure [Baseline and on day 30]: measured by SphygmoCor at 0 and 2 hours postconsumption
  • Heart rate [Baseline and on day 30]: measured by SphygmoCor at 0 and 2 hours postconsumption
  • Ambulatory blood pressure [Baseline and on day 30]: measured by Tonoport V , 24 h continuous measurement postconsumption

Other outcomes

  • Plasma (poly)phenol metabolites [Baseline and on day 30]: measured by ultra-performance liquid chromatography quadrupole time of flight mass spectrometry (UPLC-Q-TOF MS) at 0 and 2 hours postconsumption
  • Urinary (poly)phenol metabolites [Baseline and on day 30]: measured by ultra-performance liquid chromatography quadrupole time of flight mass spectrometry (UPLC-Q-TOF MS) at 0-12 and 12-24 hours post consumption

+Eligibility

Sex: Female, ages: 50 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Post-menopausal female subjects without clinical signs or symptoms of cardiovascular disease, no menstruation cycle for more than 1 year, postmenopausal status conformed by female hormone analysis
* > 50 years

Exclusion Criteria:

* cardiovascular disease
* acute inflammation
* cardiac arrhythmia
* renal failure
* heart failure (NYHA II-IV)
* diabetes mellitus
* C-reactive protein > 0.5 mg/dL
* malignant disease
* hypotension (≤100 / 60 mm Hg)

+Locations (1)

FacilityCityCountryStatus
Division of Cardiology, Pulmonary Disease and Vascular Medicine, University Hospital DuesseldorfDüsseldorfGermany

+Investigators

  • Ana Rodriguez-Mateos, PhD, Principal investigator, Division of Cardiology, Pulmonary Disease and Vascular Medicine, University Hospital Duesseldorf
  • Christian Heiss, MD, Study chair, Division of Cardiology, Pulmonary Disease and Vascular Medicine, University Hospital Duesseldorf

My Notes